Bacteriophage Therapy Market
Bacteriophage Therapy Market Forecasts to 2030 - Global Analysis By Product (Phage Probiotics, Phage Therapeutic and Other Products), Type (Lytic, Lysogenic and Other Types), Targeted Bacteria (Escherichia Coli, Staphylococcus Aureus, Streptococcus, Pseudomonas Aeruginosa, Salmonella and Other Targeted Bacteria), Disease Indication, Route of Administration, Distribution Channel, Application, End User and By Geography
According to Stratistics MRC, the Global Bacteriophage Therapy Market is accounted for $46.59 million in 2023 and is expected to reach $80.90 million by 2030 growing at a CAGR of 8.2% during the forecast period. Bacteriophages are viruses that only attack and kill bacteria. They are among the most prevalent biological organisms capable of battling and eliminating bacteria with multiple drug resistances. Phages can eliminate the bacteria causing an infection when all other antibiotics have failed to treat it, enabling medical professionals to save a life. Additionally, bacteriophages are being investigated as an alternative to antibiotics. In this therapy, viruses are used to inject bacteria with their genetic material so that the bacteria can use the machinery of their hosts to grow.
According to the Centers for Disease Control and Prevention (CDC), antibiotic-resistant bacterial infections affect approximately 33 000 people in Europe each year. Antibiotic resistance is predicted to increase globally, creating considerable demand for bacteriophages.
Market Dynamics:
Driver:
Increasing antibiotic resistance
The overuse and abuse of antibiotics in both human medicine and agriculture have serious consequences, including the rise in antibiotic resistance. Antibiotic-resistant superbugs have emerged as a result of this worrying trend, necessitating the urgent need for alternative therapies like bacteriophage therapy. Moreover, bacteriophages are naturally occurring viruses that target and destroy bacteria, making them a promising weapon against these pathogens that are drug-resistant. Researchers are investigating how to effectively target and get rid of these tough bacterial strains using phage cocktails and specially created phages.
Restraint:
Insufficient clinical data and regulatory obstacles
It is difficult to persuade regulatory agencies of the safety and effectiveness of bacteriophage therapy because there aren't many large-scale, randomized controlled trials that can provide sufficient clinical evidence. However, it may take longer to get a product approved for the market and cost more money because of the strict regulatory environment for new therapies and the requirement for extensive clinical data. While overcoming these challenges, developers must also address issues with the consistency and quality of phage preparations used in clinical trials.
Opportunity:
Investments in research and development
Innovation in bacteriophage therapy is accelerating as a result of the surge in R&D spending. Phage engineering, the creation of phage libraries, and the combination of phage therapy with other therapeutic modalities like immunotherapies or antibiotics are all topics of active research. Moreover, this dynamic environment encourages a deeper comprehension of phage biology and its clinical applications, in addition to diversifying the therapeutic toolbox.
Threat:
Regulatory issues and a lack of robust clinical data
Lack of large-scale, top-notch clinical data is one of the biggest threats to the bacteriophage therapy market. Because there have been relatively few clinical trials for bacteriophage therapy, regulatory agencies may delay approvals and raise development costs. Furthermore, regulatory agencies need strong clinical evidence to approve new therapies. It can be challenging and time-consuming for developers to navigate the regulatory environment for novel therapies.
Covid-19 Impact:
The bacteriophage therapy market has been affected in different ways by the COVID-19 pandemic. Although bacteriophages and other alternative therapies have received more attention due to the increased focus on infectious diseases and antibiotic resistance, the pandemic has also focused more resources, attention, and research efforts on COVID-19. Due to supply chain issues, bacteriophage therapy clinical trials and research were delayed, and some production interruptions happened. Despite this, the pandemic brought attention to the need for a wider range of treatment options, which may hasten the adoption of bacteriophage therapy in the post-pandemic era, particularly for persistent bacterial threats in healthcare settings and antibiotic-resistant infections.
The Urinary Tract Infections segment is expected to be the largest during the forecast period
In the market for bacteriophage therapy, the urinary tract infections (UTIs) segment commands the largest share. Each year, millions of people experience UTIs, which are among the most prevalent bacterial infections. Moreover, bacteriophage therapy has become a promising alternative due to the rise in antibiotic-resistant strains that cause UTIs. It is a compelling option for both simple and complex UTIs due to its effectiveness in targeting particular uropathogenic bacteria. Further boosting the market potential for bacteriophage-based treatments in this market are the recurrent nature of UTIs and the limitations of antibiotics in preventing relapses.
The Antimicrobial Drug Discovery segment is expected to have the highest CAGR during the forecast period
In the market for bacteriophage therapy, antimicrobial drug discovery is growing at the highest CAGR. There has been an increase in funding and research into finding new antimicrobial agents as a result of the growing concern about antibiotic resistance around the world. The ability of bacteriophages to target and destroy bacteria that are resistant to antibiotics has attracted a lot of interest in drug discovery efforts. Furthermore, the ongoing investigation of bacteriophages potential for locating and creating novel antimicrobial remedies—solutions that are urgently required to address the mounting problem of drug-resistant infections—is the primary driver of this market's rapid growth.
Region with largest share:
The largest market share for bacteriophage therapy is anticipated to be in the North American region. A number of elements, such as a strong healthcare infrastructure, a high incidence of infections caused by bacteria resistant to antibiotics, significant investments in research and development, and a supportive regulatory environment, can be credited for this dominance. The region's thriving biotechnology and pharmaceutical sectors, along with the growing use of bacteriophage therapy in clinical settings, place North America as a market leader. Additionally, bacteriophage therapy has expanded more quickly in North America thanks to partnerships between academic institutions, pharmaceutical companies, and governmental organizations, where it now accounts for the largest market share.
Region with highest CAGR:
In the global market for bacteriophage therapy, Asia-Pacific is growing at the highest CAGR. This rapid expansion is a result of a number of factors, including the heavy prevalence of infections that are resistant to antibiotics, the expanding healthcare industry, and growing public awareness of the potential advantages of bacteriophage therapy. With a focus on creating efficient production techniques and extending clinical applications, the Asia-Pacific region is seeing significant investments in research and development. Furthermore, collaborations between local academic institutions, pharmaceutical firms from abroad, and regional biotechnology companies are promoting innovation and expanding the market.
Key players in the market
Some of the key players in Bacteriophage Therapy market include InnoPhage Ltd, Eliava Biopreparations Ltd., Adaptive Phage Therapeutics, Inc, Nextbiotics, Armata Pharmaceuticals Inc., Enbiotix Inc., Eligo Bioscience SA, BiomX Ltd., Phagomed Biopharma GmbH, Intodeworld Inc., Phi Therapeutics, ContraFect Corporation, Locus Biosciences Inc., Intralytix Inc., PhagePro Inc., Pherecydes Pharma and TechnoPhage SA.
Key Developments:
In May 2023, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that have exceptionally broad coverage against antibiotic resistant bacteria.
In January 2023, Armata Pharmaceuticals, Inc., a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that it has closed a secured convertible credit agreement with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc, Armata's largest shareholder.
In July 2022, Micro biome firm BiomX is to continue collaborating with pharma giants Boehringer Ingelheim in a partnership that looks to identify biomarkers for inflammatory bowel disease (IBD). BiomX Ltd. The agreement, the second one between the two firms, uses BiomX’s XMarker micro biome-based biomarker discovery platform to aid in identifying IBD-linked pathogenic bacterium. Additional agreement terms see BiomX receive research payments with Boehringer able to negotiate an exclusive right to biomarkers discovered under the collaboration.
Products Covered:
• Phage Probiotics
• Phage Therapeutic
• Other Products
Types Covered:
• Lytic
• Lysogenic
• Other Types
Targeted Bacterias Covered:
• Escherichia Coli
• Staphylococcus Aureus
• Streptococcus
• Pseudomonas Aeruginosa
• Salmonella
• Other Targeted Bacterias
Disease Indications Covered:
• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Other Disease Indications
Route of Administrations Covered:
• Oral
• Topical
• Parenteral
Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Applications Covered:
• Skin Infection Treatment
• Gastroenterology
• Wound Prophylaxis
• Respiratory Infections Treatment
• Urogenital Infection Treatment
• Diagnostic
• Antimicrobial Drug Discovery
• Veterinary Medicines
• Other Applications
End Users Covered:
• Hospitals & Clinics
• Academic Research Organizations & Institutes
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Bacteriophage Therapy Market, By Product
5.1 Introduction
5.2 Phage Probiotics
5.3 Phage Therapeutic
5.4 Other Products
6 Global Bacteriophage Therapy Market, By Type
6.1 Introduction
6.2 Lytic
6.3 Lysogenic
6.4 Other Types
7 Global Bacteriophage Therapy Market, By Targeted Bacteria
7.1 Introduction
7.2 Escherichia Coli
7.3 Staphylococcus Aureus
7.4 Streptococcus
7.5 Pseudomonas Aeruginosa
7.6 Salmonella
7.7 Other Targeted Bacterias
8 Global Bacteriophage Therapy Market, By Disease Indication
8.1 Introduction
8.2 Urinary Tract Infections
8.3 Chronic Otitis
8.4 Dental Extraction
8.5 Chronic Ulcerative Colitis
8.6 Bone Infection
8.7 Wound and Skin Infections
8.8 Cystic Fibrosis
8.9 Other Disease Indications
9 Global Bacteriophage Therapy Market, By Route of Administration
9.1 Introduction
9.2 Oral
9.3 Topical
9.4 Parenteral
10 Global Bacteriophage Therapy Market, By Distribution Channel
10.1 Introduction
10.2 Hospital Pharmacies
10.3 Retail Pharmacies
10.4 Online Pharmacies
11 Global Bacteriophage Therapy Market, By Application
11.1 Introduction
11.2 Skin Infection Treatment
11.3 Gastroenterology
11.4 Wound Prophylaxis
11.5 Respiratory Infections Treatment
11.6 Urogenital Infection Treatment
11.7 Diagnostic
11.8 Antimicrobial Drug Discovery
11.9 Veterinary Medicines
11.10 Other Applications
12 Global Bacteriophage Therapy Market, By End User
12.1 Introduction
12.2 Hospitals & Clinics
12.3 Academic Research Organizations & Institutes
12.4 Other End Users
13 Global Bacteriophage Therapy Market, By Geography
13.1 Introduction
13.2 North America
13.2.1 US
13.2.2 Canada
13.2.3 Mexico
13.3 Europe
13.3.1 Germany
13.3.2 UK
13.3.3 Italy
13.3.4 France
13.3.5 Spain
13.3.6 Rest of Europe
13.4 Asia Pacific
13.4.1 Japan
13.4.2 China
13.4.3 India
13.4.4 Australia
13.4.5 New Zealand
13.4.6 South Korea
13.4.7 Rest of Asia Pacific
13.5 South America
13.5.1 Argentina
13.5.2 Brazil
13.5.3 Chile
13.5.4 Rest of South America
13.6 Middle East & Africa
13.6.1 Saudi Arabia
13.6.2 UAE
13.6.3 Qatar
13.6.4 South Africa
13.6.5 Rest of Middle East & Africa
14 Key Developments
14.1 Agreements, Partnerships, Collaborations and Joint Ventures
14.2 Acquisitions & Mergers
14.3 New Product Launch
14.4 Expansions
14.5 Other Key Strategies
15 Company Profiling
15.1 InnoPhage Ltd
15.2 Eliava Biopreparations Ltd.
15.3 Adaptive Phage Therapeutics, Inc
15.4 Nextbiotics
15.5 Armata Pharmaceuticals Inc.
15.6 Enbiotix Inc.
15.7 Eligo Bioscience SA
15.8 BiomX Ltd.
15.9 Phagomed Biopharma GmbH
15.10 Intodeworld Inc.
15.11 Phi Therapeutics
15.12 ContraFect Corporation
15.13 Locus Biosciences Inc.
15.14 Intralytix Inc.
15.15 PhagePro Inc.
15.16 Pherecydes Pharma
15.17 TechnoPhage SA
List of Tables
1 Global Bacteriophage Therapy Market Outlook, By Region (2021-2030) ($MN)
2 Global Bacteriophage Therapy Market Outlook, By Product (2021-2030) ($MN)
3 Global Bacteriophage Therapy Market Outlook, By Phage Probiotics (2021-2030) ($MN)
4 Global Bacteriophage Therapy Market Outlook, By Phage Therapeutic (2021-2030) ($MN)
5 Global Bacteriophage Therapy Market Outlook, By Other Products (2021-2030) ($MN)
6 Global Bacteriophage Therapy Market Outlook, By Type (2021-2030) ($MN)
7 Global Bacteriophage Therapy Market Outlook, By Lytic (2021-2030) ($MN)
8 Global Bacteriophage Therapy Market Outlook, By Lysogenic (2021-2030) ($MN)
9 Global Bacteriophage Therapy Market Outlook, By Other Types (2021-2030) ($MN)
10 Global Bacteriophage Therapy Market Outlook, By Targeted Bacteria (2021-2030) ($MN)
11 Global Bacteriophage Therapy Market Outlook, By Escherichia Coli (2021-2030) ($MN)
12 Global Bacteriophage Therapy Market Outlook, By Staphylococcus Aureus (2021-2030) ($MN)
13 Global Bacteriophage Therapy Market Outlook, By Streptococcus (2021-2030) ($MN)
14 Global Bacteriophage Therapy Market Outlook, By Pseudomonas Aeruginosa (2021-2030) ($MN)
15 Global Bacteriophage Therapy Market Outlook, By Salmonella (2021-2030) ($MN)
16 Global Bacteriophage Therapy Market Outlook, By Other Targeted Bacterias (2021-2030) ($MN)
17 Global Bacteriophage Therapy Market Outlook, By Disease Indication (2021-2030) ($MN)
18 Global Bacteriophage Therapy Market Outlook, By Urinary Tract Infections (2021-2030) ($MN)
19 Global Bacteriophage Therapy Market Outlook, By Chronic Otitis (2021-2030) ($MN)
20 Global Bacteriophage Therapy Market Outlook, By Dental Extraction (2021-2030) ($MN)
21 Global Bacteriophage Therapy Market Outlook, By Chronic Ulcerative Colitis (2021-2030) ($MN)
22 Global Bacteriophage Therapy Market Outlook, By Bone Infection (2021-2030) ($MN)
23 Global Bacteriophage Therapy Market Outlook, By Wound and Skin Infections (2021-2030) ($MN)
24 Global Bacteriophage Therapy Market Outlook, By Cystic Fibrosis (2021-2030) ($MN)
25 Global Bacteriophage Therapy Market Outlook, By Other Disease Indications (2021-2030) ($MN)
26 Global Bacteriophage Therapy Market Outlook, By Route of Administration (2021-2030) ($MN)
27 Global Bacteriophage Therapy Market Outlook, By Oral (2021-2030) ($MN)
28 Global Bacteriophage Therapy Market Outlook, By Topical (2021-2030) ($MN)
29 Global Bacteriophage Therapy Market Outlook, By Parenteral (2021-2030) ($MN)
30 Global Bacteriophage Therapy Market Outlook, By Distribution Channel (2021-2030) ($MN)
31 Global Bacteriophage Therapy Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
32 Global Bacteriophage Therapy Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
33 Global Bacteriophage Therapy Market Outlook, By Online Pharmacies (2021-2030) ($MN)
34 Global Bacteriophage Therapy Market Outlook, By Application (2021-2030) ($MN)
35 Global Bacteriophage Therapy Market Outlook, By Skin Infection Treatment (2021-2030) ($MN)
36 Global Bacteriophage Therapy Market Outlook, By Gastroenterology (2021-2030) ($MN)
37 Global Bacteriophage Therapy Market Outlook, By Wound Prophylaxis (2021-2030) ($MN)
38 Global Bacteriophage Therapy Market Outlook, By Respiratory Infections Treatment (2021-2030) ($MN)
39 Global Bacteriophage Therapy Market Outlook, By Urogenital Infection Treatment (2021-2030) ($MN)
40 Global Bacteriophage Therapy Market Outlook, By Diagnostic (2021-2030) ($MN)
41 Global Bacteriophage Therapy Market Outlook, By Antimicrobial Drug Discovery (2021-2030) ($MN)
42 Global Bacteriophage Therapy Market Outlook, By Veterinary Medicines (2021-2030) ($MN)
43 Global Bacteriophage Therapy Market Outlook, By Other Applications (2021-2030) ($MN)
44 Global Bacteriophage Therapy Market Outlook, By End User (2021-2030) ($MN)
45 Global Bacteriophage Therapy Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
46 Global Bacteriophage Therapy Market Outlook, By Academic Research Organizations & Institutes (2021-2030) ($MN)
47 Global Bacteriophage Therapy Market Outlook, By Other End Users (2021-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
List of Figures
Figure 1 Global Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 2 North America Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 3 US Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 4 Canada Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 5 Mexico Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 6 Europe Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 7 Germany Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 8 UK Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 9 Italy Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 10 France Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 11 Spain Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 12 Rest of Europe Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 13 Asia Pacific Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 14 Japan Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 15 China Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 16 India Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 17 Australia Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 18 New Zealand Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 19 South Korea Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 20 Rest of Asia Pacific Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 21 South America Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 22 Argentina Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 23 Brazil Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 24 Chile Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 25 Rest of South America Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 26 Middle East & Africa Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 27 Saudi Arabia Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 28 UAE Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 29 Qatar Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 30 South Africa Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
Figure 31 Rest of Middle East & Africa Bacteriophage Therapy Market Outlook (2021-2030) ($MN)
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
